Clinical Trials
49 trialsMC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer
Mayo Clinic
Amivantamab in Adenoid Cystic Carcinoma
University of Cincinnati
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
NRG Oncology
Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas
Dana-Farber Cancer Institute
Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study
Mayo Clinic
Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)
National Cancer Center Hospital East
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
Peking Union Medical College
Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers
M.D. Anderson Cancer Center
iPRIME
University of Chicago
Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma
Big Ten Cancer Research Consortium
Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer
Memorial Sloan Kettering Cancer Center
Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers
Memorial Sloan Kettering Cancer Center
I-MAC
Dana-Farber Cancer Institute
TROP2
National University Hospital, Singapore
9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma
Dana-Farber Cancer Institute
Arginine/Omega-3 Fatty Acids/Nucleotides Nutritional Supplement in Treating Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy
Institut du Cancer de Montpellier - Val d'Aurelle
VUBAR
Universitair Ziekenhuis Brussel
Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer
Northwestern University
ACCO
Heidelberg University
Activity of Sorafenib in Salivary Gland Cancer
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
LUPSA
Radboud University Medical Center
NISCAHN
UNICANCER
Weekly Docetaxel Plus Cisplatin as First-line Chemotherapy in Metastatic Salivary Gland Cancer Patients : a Multicenter Phase II Study
Samsung Medical Center
Cabo ASAP
Radboud University Medical Center
Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck
Abramson Cancer Center at Penn Medicine
Cetuximab in Treating Patients With Precancerous Lesions of the Upper Aerodigestive Tract
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
PACSA-ORL02
UNICANCER
SGC-AX14
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy
Mayo Clinic
Imatinib Mesylate in Treating Patients With Salivary Gland Cancer
University Health Network, Toronto
Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer
University of Washington
Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck Cancer
Medical University of South Carolina
Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia
Dana-Farber Cancer Institute
Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer
Fox Chase Cancer Center
Iressa Study in Patients With Salivary Gland Cancer
M.D. Anderson Cancer Center
Antineoplaston Therapy in Treating Patients With Advanced Head and Neck Cancer
Burzynski Research Institute
Chemo/XRT +/- Amifostine to Assess Outcomes Related to Xerostomia, Mucositis, & Dysphagia
Vanderbilt-Ingram Cancer Center
Trastuzumab in Treating Patients With Advanced Salivary Gland Cancer
Dana-Farber Cancer Institute
Title XELOX FOR SALIVARY GLAND CANCERS
Dana-Farber Cancer Institute
Gemcitabine in Treating Patients With Advanced Salivary Gland Cancer That Cannot Be Removed During Surgery
Dana-Farber Cancer Institute
Oxaliplatin and Capecitabine in Treating Patients With Relapsed or Metastatic Head and Neck Cancer
University of Miami
Docetaxel in Treating Patients With Solid Tumors
Alliance for Clinical Trials in Oncology
DOVE
Ontario Clinical Oncology Group (OCOG)
A Study of Sunitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands
University Health Network, Toronto
EF5 Compared With Other Methods of Detecting Oxygen Levels in Tumor Cells of Patients With Head and Neck Cancer
Duke University
Cisplatin Plus Gemcitabine in Treating Patients With Advanced Squamous Cell Head and Neck Cancer
Fox Chase Cancer Center
Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung Cancer
Fox Chase Cancer Center
Irinotecan and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Vanderbilt-Ingram Cancer Center
Celecoxib in Treating Patients With Early-Stage Head and Neck Cancer or Non-Small Cell Lung Cancer
Northwestern University